Padlock Therapeutics VP of Finance Salaries in Wilmington, DE | Comparably
Padlock is developing medicines targeting PADs, immune complexes in autoimmune diseases, and more. read more
EMPLOYEE
PARTICIPANTS
3
TOTAL
RATINGS
95

Padlock Therapeutics VP of Finance Salaries in Wilmington, DE

The average Padlock Therapeutics VP of Finance in Wilmington, DE earns an estimated $155,291 annually. Padlock Therapeutics' VP of Finance compensation is $51,239 less than the US average for a VP of Finance.

In Wilmington, DE, The Finance Department at Padlock Therapeutics earns $16,617 more on average than the Admin Department.

Last updated 5 years ago.

$50k
$90k
$145k
$200k
$309k
$430k
$518k
$155,291
Average Compensation
$155,291
avg. base

VP of Finance Salaries at Padlock Therapeutics

In Wilmington, DE, VPs of Finance earn $34,362 more than Accounting Managers.

Accounting Manager
$121k*
Business Analyst
$95k*
Senior Accountant
$92k*
Accountant
$71k*
Financial Analyst
$68k*
* estimated salary

Compensation at Padlock Therapeutics by Department

In Wilmington, DE, The Finance Department averages $16,617 more than the Admin Department, and $11,093 less than the IT Department

IT
$95,656 Avg. total comp.
+$11k
Finance
$84,563 Avg. total comp.
Admin
$67,946 Avg. total comp.
-$17k

VP of Finance Compensation by Gender (All Companies)

The average female VP of Finance at companies similar size to Padlock Therapeutics reported making $188,034, while the average male VP of Finance at similar sized companies reported making $216,094.

VP of Finance Compensation by Ethnicity (All Companies)

The average Caucasian VP of Finance at companies similar size to Padlock Therapeutics reported making $207,596, while the average Hispanic or Latino VP of Finance at similar sized companies reported making $170,500.

How VPs of Finance at Padlock Therapeutics Rate Their Compensation

The majority of VPs of Finance at Padlock Therapeutics believe they're compensated fairly. 50% of VPs of Finance at Padlock Therapeutics say they receive annual bonuses, and the vast majority (100%) are satisfied with their benefits. See more compensation ratings at Padlock Therapeutics

×
Rate your company